DCPH News and Press, Deciphera Pharmaceuticals Inc. From 10/31/23

Deciphera Pharmaceuticals Inc. (DCPH) is expected to report $-0.6 for Q3 2023

2023-10-30 07:39:24 ET More on Deciphera Deciphera Pharmaceuticals Pipeline Is Underwhelming Deciphera Pharmaceuticals: Clawing Its Way Back Deciphera Pharmaceuticals, Inc. (DCPH) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Deciphe...

2023-10-30 07:11:48 ET More on Deciphera Pharmaceuticals Deciphera Pharmaceuticals Pipeline Is Underwhelming Deciphera Pharmaceuticals: Clawing Its Way Back Deciphera Pharmaceuticals, Inc. (DCPH) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant R...

– Third Quarter 2023 Total Revenue of $43.3 Million; Net Product Revenue for QINLOCK ® (ripretinib) Increased 29% to $41.8 Million Compared to Third Quarter 2022 – – Announced Positive Top-line Results for MOTION Pivotal Phase 3 Study of Vimseltinib f...

– MOTION Study Met Primary Endpoint with Objective Response Rate (ORR) at Week 25 of 40% Compared to 0% for Placebo (p<0.0001) – – MOTION Study Met All Key Secondary Endpoints with Statistically Significant and Clinically Meaningful Improvements at Week 25 Compared...

2023-10-26 10:29:06 ET Summary Our estimates show that Qinlock 2L KIT exon 11+17/18 mutation indication sales guidance is unlikely to be achieved due to fractional incidence. Deciphera Pharmaceuticals is expecting a Phase III MOTION trial topline readout this quarter, which is unl...

Medison Pharma Announces Public Formulary Listing of QINLOCK® (ripretinib) in Canadian Provinces: Ontario and Quebec for Advanced Gastrointestinal Stromal Tumor (GIST) Treatment Canada NewsWire This marks a significant step forward in the multi-regional partnership betwee...

2023-08-22 05:06:03 ET Summary Deciphera Pharmaceuticals is focused on the development of their multikinase inhibitor ripretinib for the treatment of gastrointestinal stromal tumor. The INSIGHT study is comparing ripretinib against sunitinib in GIST patients who failed imatinib th...

2023-08-19 07:40:00 ET Most people have either had cancer themselves or know someone who has. According to the American Cancer Society, 1 in 3 people in the U.S. will be diagnosed with one of the numerous forms of cancer. Deciphera Pharmaceuticals (NASDAQ: DCPH) , Mirati Thera...

2023-08-11 15:30:19 ET Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) were up more than 17% for the week as of Friday at 2 p.m. ET, according to data provided by S&P Global Market Intelligence . The biotech company's stock closed last week at $13.08, then rose to a h...